Literature DB >> 19119604

[Enhancement of radio sensitivity in nasopharyngeal cancer cells by the own regulation of VEGF expression after adenovirus-E1A gene therapy].

Rongrong Zhou1, Zhiqiang Xiao, Yuping Liao, Huaping Xiao.   

Abstract

OBJECTIVE: To determine the effect of Ad-E1A gene therapy on the radiosensitivity of nasopharyngeal carcinoma cell by downregulating the expression of VEGF in vitro.
METHOD: The human nasopharyngeal carcinoma CNE-2Z cell lines were investigated. The recombinant adenovirus vector containing E1A gene was used for this study. After CNE-2Z cells was treated with PBS, Ad-beta-gal and Ad-E1A for 48 h, the three groups were irradiated in different doses at 0, 2.4, 6, 8 and 10 Gy, the cytotoxicity was determined by MTT assay and cell cycle was analysis by flow cytometry. The VEGF expression were evaluated by RT-PCR assay and immunocytochemical analysis. RESULT: Significant cell deaths by IR were observed in a dose dependent manner in the three group CNE-2Z cells. After transduction of the E1A gene into CNE-2Z cells, the sensitivity of these cells to radiation was enhanced than the PBS treated group and Ad-beta-gal treated group. Cell growth inhibition in Ad-E1A group by IR was strongly enhanced than Ad-beta-gal treated group and PBS treated group. RT-PCR assay and immunocytochemical analysis showed VEGF expression was downregulated in Ad-E1A treated group.
CONCLUSION: E1A gene therapy can effectively enhance the nasopharyngeal carcinoma cell sensitivity to the radiotherapy by down-regulating VEGF expression. These findings may pave the way for efficient radiation-gene therapy to NPC in future.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19119604

Source DB:  PubMed          Journal:  Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi        ISSN: 1001-1781


  1 in total

1.  Clinical trial of thalidomide combined with radiotherapy in patients with esophageal cancer.

Authors:  Jing-Ping Yu; Su-Ping Sun; Zhi-Qiang Sun; Xin-Chu Ni; Jian Wang; Yi Li; Li-Jun Hu; Dong-Qing Li
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.